Business
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
Preclinical findings demonstrate superior pharmacological activity, offering a differentiated mechanism-of-action to enhance anti-tumor immunity in advanced
About this update from Agenus Inc.
[{"type":"text","content":"\nPreclinical findings demonstrate superior pharmacological activity, offering a differentiated mechanism-of-action to enhance anti-tumor immunity in advanced solid cancers\n\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nAgenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.\n\n\nIn non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to conventional TIGIT antibodies. This novel, Fc-enhanced, bispecific antibody is differentiated from conventional TIGIT monoclonal antibodies by optimally targeting two critical immune checkpoint receptors in the same pathway, TIGIT and CD96. BMS-986442 (AGEN1777) leverages Agenus’ proprietary Fc-engineering platform to harness novel mechanisms of action that extend beyond the capabilities of conventional anti-TIGIT therapy. This innovative strategy could represent a promising approach to overcome the limitations of current anti-TIGIT therapies.\n\n\n“Immune checkpoint blockade has emerged as a powerful strategy in enhancing anti-tumor immunity. However, conventional TIGIT antibodies have faced limitations with monotherapy activity in clinical settings,” said Dhan Chand, Ph.D., Vice President of Research. “BMS-986442 has the potential to address these challenges through Fc modification and the targeting of complementary pathways.”\n\n\nPresentation Details:\n\n\nAbstract Title: BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models\nAbstract Number: 3915\nPresenting Author: Dhan Chand\nSession: Immune Targets and Therapies\nPresentation Session Date and Time: Monday April 8, 2024, 2:30 p.m. – 4:30 p.m. PST\n\n\nData presented at the conference will be available to view in the publications section of the Agenus website (https://agenusbio.com/publications) following the AACR Meeting.\n\n\nAbout BMS-986442 (AGEN1777)\n\n\nBMS-986442 (AGEN1777) is being developed in partnership between Agenus and Bristol Myers Squibb. The TI...